JP Morgan Private Capital, JP Morgan’s venture capital and growth equity investment team has held the final close of 270 Life Sciences Private Capital Fund I, above its $500m target.
LSPCF received commitments from institutional allocators, strategic corporate partners, family offices and HNWIs across North America, Europe, the Middle East and Asia, as well as JPMorgan Chase & Co. The fund close was led by CIO Stephen Squinto and Managing Partner Gaurav Gupta.
LSPCF invests in private biotechnology companies spanning cardiometabolic disease, oncology, immunology and genetic medicines.
Source:Private Equity Wire
Can’t stop reading? Read more
Blackstone boosts hospitality portfolio with $200m Sunseeker Resort deal
Blackstone boosts hospitality portfolio with $200m Sunseeker Resort deal Blackstone Real Estate...
Apollo appoints Brian Chu to lead operational value creation platform APPS
Apollo appoints Brian Chu to lead operational value creation platform APPS Apollo Global...
TDR Capital eyes £2bn continuation deal for David Lloyd Leisure
TDR Capital eyes £2bn continuation deal for David Lloyd Leisure TDR Capital is nearing a £2bn...
